Ascletis Pharma Inc.

Direct answer

Ascletis Pharma Inc. is publicly traded on HKSE under the ticker 1672.HK.

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus;...

Can you invest in Ascletis Pharma Inc.?

Yes. Ascletis Pharma Inc. is publicly traded on HKSE under the ticker 1672.HK.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Ascletis Pharma Inc.

Detailed equity research is provided by MarketSnap.